Co-Authors
This is a "connection" page, showing publications co-authored by Ioana Berindan-Neagoe and Solomon Habtemariam.
Connection Strength
1.380
-
Lessons from SARS and MERS remind us of the possible therapeutic effects of implementing a siRNA strategy to target COVID-19: Shoot the messenger! J Cell Mol Med. 2020 09; 24(17):10267-10269.
Score: 0.223
-
Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy? Arch Med Res. 2020 10; 51(7):733-735.
Score: 0.221
-
Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2. Pharmacol Res. 2020 07; 157:104853.
Score: 0.220
-
Should we try the antiinflammatory natural product, celastrol, for COVID-19? Phytother Res. 2020 06; 34(6):1189-1190.
Score: 0.220
-
Possible Targets and Therapies of SARS-CoV-2 Infection. Mini Rev Med Chem. 2020; 20(18):1900-1907.
Score: 0.215
-
Rationale for Effective Prophylaxis Against COVID-19 Through Simultaneous Blockade of Both Endosomal and Non-Endosomal SARS-CoV-2 Entry into Host Cell. Clin Transl Sci. 2021 03; 14(2):431-433.
Score: 0.058
-
Glucose-6-phosphate dehydrogenase deficiency and SARS-CoV-2 mortality: Is there a link and what should we do? Clin Biochem. 2020 Dec; 86:31-33.
Score: 0.056
-
Various interferon (IFN)-inducible transmembrane (IFITM) proteins for COVID-19, is there a role for the combination of mycophenolic acid and interferon? Biochimie. 2020 Oct; 177:50-52.
Score: 0.056
-
A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19. Arch Med Res. 2020 10; 51(7):631-635.
Score: 0.056
-
Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2. Arch Med Sci. 2020; 16(3):519-521.
Score: 0.055